Nanobiomaterials in support of drug delivery related issues

被引:22
作者
Joseph, X. [1 ]
Akhil, V [1 ]
Arathi, A. [1 ]
Mohanan, P., V [1 ]
机构
[1] Sree Chitra Tirunal Inst Med Sci & Technol Govt I, Toxicol Div, Biomed Technol Wing, Trivandrum 695012, Kerala, India
来源
MATERIALS SCIENCE AND ENGINEERING B-ADVANCED FUNCTIONAL SOLID-STATE MATERIALS | 2022年 / 279卷
关键词
Nanobiomaterials; Drug delivery; Toxicity; Controlled release; Surface modification; SENSITIVE LIPOSOME; CHITOSAN NANOPARTICLES; ORAL BIOAVAILABILITY; COLORIMETRIC ASSAY; RISK-ASSESSMENT; IN-VITRO; NANOMATERIALS; RELEASE; PH; TEMPERATURE;
D O I
10.1016/j.mseb.2022.115680
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
Nanobiomaterials have been widely accepted as potential drug delivery agents over the past decade. A wide variety of materials have been utilized as drug delivery carriers for various diseases like Cancer, Alzheimer's etc. Being the leading cause of death worldwide, effective drug delivery to cancer cells by using nanomaterials has become the most fascinating and dynamic regions of research. The decreased size of these materials increased permeability through physiological barriers, and increased cell to cell interactions are the properties that are highly suitable for drug delivery applications. Biocompatibility and biodegradability are added advantages of using nano biomaterials as drug delivery systems. However, to transfer the nanobiomaterials for advanced clinical applications, a detailed study should be established considering the interactions of these nanobiomaterials with the physiological environment. Moreover, the need for extensive toxicity studies will open up a new window for the effective translation of these materials into clinical drug delivery carriers. The integration of nanomedicine and drug delivery system framework is unquestionably the pattern that will stay in the field of innovative work for quite a long time. Herein, we highlight the challenges of nanobiomaterials related to drug delivery and the possible strategies utilized to overcome the drug delivery-related issues.
引用
收藏
页数:16
相关论文
共 153 条
[1]   tRNA conjugation with chitosan nanoparticles: An AFM imaging study [J].
Agudelo, D. ;
Kreplak, L. ;
Tajmir-Riahi, H. A. .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2016, 85 :150-156
[2]   Optimal Method to Stimulate Cytokine Production and Its Use in Immunotoxicity Assessment [J].
Ai, Wenchao ;
Li, Haishan ;
Song, Naining ;
Li, Lei ;
Chen, Huiming .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2013, 10 (09) :3834-3842
[3]   Nanomedicines for overcoming biological barriers [J].
Alonso, MJ .
BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (03) :168-172
[4]   Controlling Cell Behavior through the Design of Biomaterial Surfaces: A Focus on Surface Modification Techniques [J].
Amani, Hamed ;
Arzaghi, Hamidreza ;
Bayandori, Mehrdad ;
Dezfuli, Amin Shiralizadeh ;
Pazoki-Toroudi, Hamidreza ;
Shafiee, Abbas ;
Moradi, Lida .
ADVANCED MATERIALS INTERFACES, 2019, 6 (13)
[5]   A novel smart PEGylated gelatin nanoparticle for co-delivery of doxorubicin and betanin: A strategy for enhancing the therapeutic efficacy of chemotherapy [J].
Amjadi, Sajed ;
Hamishehkar, Hamed ;
Ghorbani, Marjan .
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2019, 97 :833-841
[6]   Effect assessment of engineered nanoparticles in solid media - Current insight and the way forward [J].
Amorim, Monica J. B. ;
Roca, Carlos P. ;
Scott-Fordsmand, Janeck J. .
ENVIRONMENTAL POLLUTION, 2016, 218 :1370-1375
[7]  
[Anonymous], 2016, Memorandum for Capturing and Execution Reporting of Individual Flight Test Costs
[8]   Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay: A quantitative method for oxidative stress assessment of nanoparticle-treated cells [J].
Aranda, A. ;
Sequedo, L. ;
Tolosa, L. ;
Quintas, G. ;
Burello, E. ;
Castell, J. V. ;
Gombau, L. .
TOXICOLOGY IN VITRO, 2013, 27 (02) :954-963
[9]   Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options [J].
Aungst, Bruce J. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (04) :921-929
[10]   Regulating Nanomedicine - Can the FDA Handle It? [J].
Bawa, Raj .
CURRENT DRUG DELIVERY, 2011, 8 (03) :227-234